| Summary: | 碩士 === 國立交通大學 === 生物科技學系 === 105 === Pancreatic cancer is one of the leading cause of cancer death. It carries a dismal prognosis because of lacking the biomarkers for early detection and effective therapeutic options. The 5-year survival rate of pancreatic cancer is only 8%. Our laboratory found out that both valeryl-L-carnitine (C5) and N-acetyl-Ser-Asp-Lys-Pro (AcSDKP) have a high-level expression in pancreatic cancer patients. C5 is a kind of amino acid derivatives which involved in metabolism in most mammals. It can convert into acetyl-CoA to produce usable chemical energy ATP through β-oxidation and TCA cycle. Anti-fibrotic peptide AcSDKP is a tetrapeptide generated from N-terminal of thymosin β4 (Tβ4) by prolyl oligopeptidase (POP). It has been found that this peptide had the ability to regulate cell proliferation and angiogenesis. Clinical studies also showed that AcSDKP overexpresses in many different types of malignant tumors. To investigate whether C5 and AcSDKP have an influence on pancreatic cancer, we treated pancreatic cancer cell lines with C5 or AcSDKP. With MTS assay, we revealed that both C5 and AcSDKP would promote proliferation rate of pancreatic cancer cell lines, Panc-1 and AsPC-1. They also regulate the expression of proliferation-related and apoptosis-related mRNA and protein. Moreover, AcSDKP was shown that it can decrease the mRNA level of E-cadherin and increase the mRNA level of Vimentin and Snail2. We conclude that C5 and AcSDKP have the potential for promoting the development of pancreatic cancer.
|
|---|
